1. Inhaled Immunotherapy Administration for Lung Cancer; Efficient? Certainly Possible
- Author
-
Chong Bai, Yan-gao Man, Giannakidis D, Haidong Huang, Florou Mc, Ilias Karapantzos, Naim Benhassen, Michail Karanikas, Isaak Kesisoglou, Chrysanthi Karapantzou, Liuhua Wang, Chrysanthi Sardeli, Konstantinos Sapalidis, Konstantina Boniou, Koulouris C, Mantalovas S, Yang Wen, Laskou S, P. Zarogoulidis, Wolfgang Hohenforst-Schmidt, Aikaterini Amaniti, Christoforos Kosmidis, and Thomaidis
- Subjects
0301 basic medicine ,Oncology ,medicine.medical_specialty ,medicine.medical_treatment ,Ipilimumab ,Pembrolizumab ,03 medical and health sciences ,0302 clinical medicine ,Internal medicine ,Medicine ,ipilimumab ,Lung cancer ,nivolumab ,Second line treatment ,Lung ,business.industry ,Immunotherapy ,medicine.disease ,lung cancer ,030104 developmental biology ,medicine.anatomical_structure ,030220 oncology & carcinogenesis ,pembrolizumab ,Non small cell ,Nivolumab ,business ,nsclc ,Research Paper ,medicine.drug - Abstract
Lung cancer is still diagnosed at a late stage in most lung cancer patients. Regarding Non-small Cell lung cancer there are novel therapies such as; tyrosine kinase inhibitors and immunotherapy. Currently we have two immunotherapies that can be used either as first-line treatment or second line treatment; pembrolizumab and nivolumab. A third one is being investigated as a combination of immunotherapy; ipilimumab. Aerosol treatment has been investigated for many diseases not only for the lung, but also for systematic diseases. The design of cups was found the most significant factor in producing significant effects. The comparison of cups reveals the design J as the most capable of reducing the droplets at a minimum size of mass median aerodynamic diameter (MMAD) MMAD=1.99. Drug effect comes second in sequence (F=62.04) showing that nivolumab is the most drastic preparation at low particle sizes (1.89), two drugs share an intermediate particle diameter (pembrolizumab and ipilimumab). In total drugs demonstrate a decreasing droplet size: Ipilimumab>Pembrolizumab> Nivolumab.
- Published
- 2018